Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $16.25.
A number of research firms recently issued reports on OCUL. Royal Bank Of Canada began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 target price for the company. William Blair began coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an “outperform” rating for the company. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Finally, Needham & Company LLC decreased their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th.
Get Our Latest Analysis on OCUL
Insiders Place Their Bets
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix during the 4th quarter valued at about $1,722,000. Charles Schwab Investment Management Inc. grew its stake in Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after acquiring an additional 21,025 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Ocular Therapeutix by 82.9% during the 4th quarter. Ameriprise Financial Inc. now owns 89,772 shares of the biopharmaceutical company’s stock valued at $767,000 after acquiring an additional 40,700 shares in the last quarter. ProShare Advisors LLC grew its stake in Ocular Therapeutix by 32.8% during the 4th quarter. ProShare Advisors LLC now owns 51,270 shares of the biopharmaceutical company’s stock valued at $438,000 after acquiring an additional 12,669 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in Ocular Therapeutix by 21.9% during the 4th quarter. Two Sigma Investments LP now owns 252,939 shares of the biopharmaceutical company’s stock valued at $2,160,000 after acquiring an additional 45,518 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.
Ocular Therapeutix Trading Down 5.1%
NASDAQ:OCUL opened at $8.30 on Friday. Ocular Therapeutix has a 12 month low of $5.34 and a 12 month high of $11.78. The firm has a fifty day simple moving average of $7.79 and a 200-day simple moving average of $7.86. The company has a current ratio of 10.22, a quick ratio of 10.14 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $1.32 billion, a P/E ratio of -7.22 and a beta of 1.42.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Recommended Stories
- Five stocks we like better than Ocular Therapeutix
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Analyst Downgrades Joby, But Overlooks Major Regulatory Wins
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- U.S. Steel Stock Burns the Bears With Surprise Upside Move
- What is the NASDAQ Stock Exchange?
- Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.